NYSE$NSPR
InspireMD Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
InspireMD reported third quarter 2023 financial results, showing revenue increase and progress in clinical trials.
InspireMD reported an 8.7% increase in revenue for Q3 2023, driven by CGuard EPS sales, and highlighted positive safety data from the C-GUARDIANS U.S. IDE clinical trial. The company also noted the expansion of CAS coverage by CMS as a positive development.
- CGuard EPS revenue reached $1.56 million in Q3 2023, an increase of nearly 9% year-over-year.
- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. IDE clinical trial.
- CMS expanded coverage of CAS to include both asymptomatic and standard risk patients.
- Gross profit increased by 19.7% to $438,000, with gross margin rising to 28.1%.
Headline financials
Revenue & EPS history
InspireMD · Revenue · Quarterly
$1.56M
Revenue by segment
InspireMD · $1.56M total across 1 segment · Q3 2023
- CGuard EPS$1.56M+8.7%100.0%
Forward guidance
InspireMD is focused on obtaining potential approval and launching CGuard EPS in the U.S. in the first half of 2025 and believes the CMS coverage determination will catalyze a stent-first approach to the treatment of carotid disease.
Tailwinds
- Potential approval and launch of CGuard EPS in the U.S. in the first half of 2025
- Compelling 30-day safety data from C-GUARDIANS presented at VIVA23
- CMS issued its final National Coverage Determination (NCD), expanding coverage of CAS to include both asymptomatic and standard risk patients
- Focus on developing products for both CAS and TCAR approaches
- Continued execution against 2023 objectives
Headwinds
- History of recurring losses and negative cash flows from operating activities
- Need to raise additional capital to meet business requirements in the future
- Market acceptance of products
- Inability to secure and maintain regulatory approvals for the sale of products
- Negative clinical trial results or lengthy product delays in key markets
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
-3.7%
Avg return
Earnings day
-7.1%
Avg return
5 days after
-12.5%
Avg return
30 days after
32%
19 / 60 earnings
Positive
+15.4%
Q4 2014
Best reaction
-26.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | +0.0% | — | |
| Q4 2025 | +0.0% | -2.8% | -24.6% | |
| Q3 2025 | -7.0% | -21.0% | -16.2% | |
| Q1 2025 | +0.0% | -9.2% | -3.8% | |
| Q4 2024 | +0.7% | +0.4% | -8.2% | |
| Q3 2024 | +2.0% | +2.8% | +25.6% | |
| Q2 2024 | -3.4% | -3.4% | -7.4% | |
| Q1 2024 | -4.2% | -4.2% | +8.3% | |
| Q4 2023 | +0.4% | -3.0% | -12.9% | |
| Q3 2023 | -6.0% | -9.0% | -26.1% | |
| Q2 2023 | +0.0% | +3.5% | +11.9% | |
| Q1 2023 | -4.3% | -2.2% | +11.4% | |
| Q4 2022 | -1.7% | -6.1% | -9.6% | |
| Q3 2022 | -13.9% | -22.2% | +5.6% | |
| Q2 2022 | -6.3% | -5.9% | -15.1% | |
| Q1 2022 | -3.9% | +1.0% | +1.9% | |
| Q4 2021 | +4.6% | -4.6% | +19.8% | |
| Q3 2021 | -1.4% | -3.4% | -14.9% | |
| Q2 2021 | -2.5% | -4.8% | +7.8% | |
| Q1 2021 | +0.6% | -3.2% | +23.6% | |
| Q4 2020 | -11.4% | -4.9% | -20.5% | |
| Q3 2020 | +2.9% | +0.0% | +0.0% | |
| Q2 2020 | -2.1% | -2.1% | -27.7% | |
| Q1 2020 | +13.5% | +6.8% | -24.3% | |
| Q4 2019 | -22.0% | -35.4% | -18.3% | |
| Q3 2019 | -26.3% | -33.8% | -31.6% | |
| Q2 2019 | -19.9% | -18.0% | -11.4% | |
| Q1 2019 | -19.4% | -24.3% | -14.4% | |
| Q4 2018 | -10.0% | -12.5% | -46.6% | |
| Q3 2018 | -4.2% | -8.3% | -20.8% | |
| Q2 2018 | +4.8% | +4.8% | -9.5% | |
| Q1 2018 | +7.3% | -2.4% | -7.3% | |
| Q4 2017 | -1.0% | -0.8% | -41.2% | |
| Q3 2017 | +0.0% | +2.6% | -64.1% | |
| Q2 2017 | -6.3% | -16.7% | -33.3% | |
| Q1 2017 | +0.0% | -7.9% | -12.7% | |
| Q4 2016 | -9.0% | -14.5% | -59.0% | |
| Q3 2016 | -4.1% | +2.4% | +22.9% | |
| Q2 2016 | -10.5% | -15.8% | -31.6% | |
| Q1 2016 | -14.3% | — | — | |
| Q4 2015 | +2.0% | — | — | |
| Q3 2015 | -15.8% | — | — | |
| Q2 2015 | -25.0% | — | — | |
| Q1 2015 | -11.5% | — | — | |
| Q4 2014 | +15.4% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +2.1% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +2.0% | — | — | |
| Q3 2013 | -3.1% | — | — | |
| Q2 2013 | -0.9% | — | — | |
| Q1 2013 | -6.0% | — | — | |
| Q4 2012 | -8.6% | — | — | |
| Q3 2012 | +1.4% | — | — | |
| Q2 2012 | +2.1% | — | — | |
| Q1 2012 | -16.8% | — | — | |
| Q4 2011 | +9.7% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +7.7% | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro